Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articles
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
NCI-sponsored trial evaluates safety and optimal dosing of immune checkpoint blockade following standard chemoradiation in locally advanced cervical cancer.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
A prospective cohort study shows combining ctDNA with PSA levels dramatically improves survival prediction in high-volume metastatic prostate cancer patients.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
